Crohn's Disease
Growing armamentarium of therapies for IBD has ‘truly revolutionized’ care
LAS VEGAS —A presenter at the Crohn’s & Colitis Congress outlined some of the newer therapies that have expanded the current “arsenal of tools” for the treatment of inflammatory bowel disease.
Atopic dermatitis may be linked to inflammatory bowel disease
An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.
Q&A: Zymfentra ‘gives patients an option’ for at-home maintenance therapy of IBD
The FDA’s approval of Zymfentra in fall 2023 offers patients the “flexibility” of a subcutaneous therapy option for moderately to severely active ulcerative colitis and Crohn’s disease, Stephen B. Hanauer, MD, told Healio in an interview.
Foreign-born patients with IBD have ‘milder’ disease, later onset, regardless of race
Inflammatory bowel disease phenotype and behavior vary by race and immigration status, with foreign-born patients of all races experiencing less severe disease and later onset than those born in the U.S., researchers reported.
Biologics have only ‘slight impact’ vs. conventional therapy on surgery-free survival in CD
The introduction of biologics as a therapeutic option for Crohn’s disease had “only a slight impact” on eventual surgery occurrence, although it may delay the first intestinal resection compared with conventional therapy, data showed.
FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals
In the second half of 2023, there were numerous landmark FDA approvals for gastroenterology and hepatology, in particular for the treatment of ulcerative colitis, with four new options squeezing into an already saturated market.
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.
Triple combination therapy ‘superior to monotherapy,’ improves remission in Crohn’s
A combination of vedolizumab, adalimumab and methotrexate resulted in endoscopic remission at week 26 in more than a third of patients with Crohn’s disease, according to data in Clinical Gastroenterology and Hepatology.
AGA recommends use of fecal calprotectin, serum CRP to inform Crohn’s disease management
Fecal calprotectin and serum C-reactive protein biomarkers can inform disease management for patients with asymptomatic or symptomatic Crohn’s disease, according to an updated clinical practice guideline from the AGA.
VIDEO: States with lower health, socioeconomic ranking have higher IBD-related mortality
VANCOUVER, British Columbia — Researchers found significant associations between state-level health disparities and poor inflammatory bowel disease-related outcomes, with low-ranking states demonstrating higher mortality rates.